| Fiscal period | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Period End Date | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 |
|---|
| Professional Services | -- | -- | -- | -- | -- | -- | -- | -- | 218.04 | 230.52 |
| Maintenance | -- | -- | -- | -- | -- | -- | -- | -- | 466.10 | 471.95 |
| Information services | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| System sales | -- | -- | -- | -- | -- | -- | -- | -- | 92.24 | 113.57 |
| Software delivery, support and maintenance | -- | 916.19 | 914.66 | 1,126.49 | 1,128.26 | 1,174.72 | 1,012.35 | 918.43 | -- | -- |
| Prepackaged medications | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Transaction processing and other | -- | -- | -- | -- | -- | -- | -- | -- | 601.49 | 557.02 |
| Client services | -- | 586.85 | 588.04 | 645.19 | 621.70 | 631.62 | 537.55 | 467.96 | -- | -- |
| Provider | 465.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Payer & Life Sciences | 122.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revenues | 588.02 | 1,503.04 | 1,502.70 | 1,771.68 | 1,749.96 | 1,806.34 | 1,549.90 | 1,386.39 | 1,377.87 | 1,373.06 |
| Restructuring and other charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Prepackaged medications | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Information services | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of revenue: Maintenance | -- | -- | -- | -- | -- | -- | -- | -- | 146.71 | 143.96 |
| Cost of revenue: Professional services | -- | -- | -- | -- | -- | -- | -- | -- | 191.92 | 215.14 |
| Cost of revenue: System sales | -- | -- | -- | -- | -- | -- | -- | -- | 35.10 | 54.25 |
| Cost of revenue: Transaction processing and other | -- | -- | -- | -- | -- | -- | -- | -- | 376.95 | 340.06 |
| Cost of revenue: Software delivery, support and maintenance | -- | 278.55 | 287.95 | 358.95 | 357.04 | 368.19 | 331.06 | 291.80 | -- | -- |
| Cost of revenue: Client services | -- | 486.22 | 530.65 | 583.11 | 565.50 | 541.39 | 459.17 | 432.04 | -- | -- |
| Cost of revenue: Amortization of software development and acquisition-related assets (a) | -- | 118.70 | 118.40 | 116.04 | 102.88 | 114.60 | 88.63 | 81.99 | 81.22 | 85.20 |
| Cost of revenue: Provider | 232.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of revenue: Payer & Life Sciences | 46.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | 308.42 | 619.57 | 565.70 | 713.58 | 724.54 | 782.16 | 671.04 | 580.57 | 545.98 | 534.46 |
| Goodwill impairment charge | -- | 0.00 | 0.00 | 25.70 | 13.47 | -- | -- | -- | -- | -- |
| Amortization of intangible assets | 60.88 | 23.11 | 25.60 | 27.22 | 26.59 | 33.75 | 25.85 | 23.17 | 31.28 | 31.25 |
| Research and development | 97.89 | 193.67 | 206.06 | 254.51 | 268.41 | 220.22 | 187.91 | 184.79 | 192.82 | 199.75 |
| Stock-based compensation expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling, general and administrative expenses | 169.20 | 313.81 | 389.94 | 419.77 | 450.97 | 486.27 | 392.87 | 339.18 | 358.68 | 419.60 |
| Restructuring and other charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Write-off of acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset impairment charge | (7.55) | (11.77) | (74.97) | (10.84) | (58.17) | 0.00 | (4.65) | (1.54) | (2.39) | (11.45) |
| Operating Income (loss) | (27.10) | 77.20 | (130.88) | (24.46) | (93.05) | 41.92 | 59.77 | 31.88 | (39.19) | (127.60) |
| Interest expense | 6.35 | 13.17 | 34.10 | 43.17 | 50.91 | 87.48 | 68.14 | 31.40 | 29.30 | 28.06 |
| Gain on sale of equity investment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Equity in net earnings of unconsolidated investments | (1.14) | 1.76 | 17.19 | 0.67 | 0.26 | 0.82 | (7.50) | (2.10) | -- | -- |
| Impairment of long-term investments | (7.58) | 0.00 | (1.58) | (0.65) | (15.49) | (165.29) | -- | -- | -- | -- |
| Interest income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other income (expense) net | (21.68) | 87.67 | 0.05 | (138.90) | 0.07 | 0.41 | 1.09 | 2.18 | 0.37 | 7.31 |
| Gain on sale of business, net | -- | 8.37 | 0.00 | 0.00 | 172.26 | -- | -- | -- | -- | -- |
| Income from operations before income taxes | (63.85) | 161.83 | (149.31) | (206.52) | 13.14 | (209.62) | (14.78) | 0.57 | (68.12) | (148.35) |
| Current: Federal | -- | -- | -- | -- | 0.84 | 0.41 | 0.32 | 0.57 | 0.84 | (0.45) |
| Current: State | -- | -- | -- | -- | 0.74 | 1.77 | 0.61 | 0.66 | 0.21 | 1.42 |
| Deferred: Federal | -- | -- | -- | -- | (5.78) | (39.24) | (18.37) | (2.93) | (0.58) | (43.54) |
| Deferred: State | -- | -- | -- | -- | 0.24 | (15.89) | (3.35) | 0.90 | (3.26) | (7.93) |
| Provision (benefit) for income taxes | (43.81) | 27.85 | (16.69) | (23.91) | 0.47 | (50.77) | (17.81) | 2.63 | (1.66) | (44.32) |
| Current tax provision - Foreign | -- | -- | -- | -- | 5.02 | 5.09 | 3.86 | 4.08 | (0.40) | 0.05 |
| Deferred tax provision - Foreign | -- | -- | -- | -- | (0.58) | (2.91) | (0.88) | (0.66) | 1.52 | 6.13 |
| Loss from continuing operations | (20.04) | 133.98 | (132.62) | (182.60) | 12.67 | (158.85) | -- | -- | -- | -- |
| Income from discontinued operations | (66.42) | (0.02) | 71.45 | 0.00 | (72.84) | 4.68 | -- | -- | -- | -- |
| Gain from sale of discontinued operations | -- | 0.65 | 1,156.50 | 0.00 | 500.47 | -- | -- | -- | -- | -- |
| Income tax effect on discontinued operations | -- | (0.17) | (394.93) | 0.00 | (32.50) | -- | -- | -- | -- | -- |
| Consolidated Net Income (Loss) | (86.46) | 134.44 | 700.41 | (182.60) | 407.81 | (154.18) | 3.03 | (2.06) | -- | -- |
| Less: Net income attributable to non-controlling interest | -- | 0.00 | 0.00 | (0.42) | (4.53) | (1.57) | 0.15 | 0.17 | -- | -- |
| Accretion of mandatory redemption value of preferred shares and accrued dividends on preferred shares | -- | -- | 0.00 | 0.00 | 48.59 | 43.85 | 28.54 | -- | -- | -- |
| Net income (loss) attributable to common stockholders | (86.46) | 134.44 | 700.41 | (182.18) | 363.74 | (196.46) | (25.65) | (2.23) | (66.45) | (104.03) |
| Loss from continuing operations | (0.18) | 1.03 | (0.83) | (1.10) | 0.10 | (1.12) | -- | -- | -- | -- |
| EPS (Basic) : Discontinued operations | (0.59) | 0.00 | 5.23 | 0.00 | 1.97 | 0.03 | -- | -- | -- | -- |
| Earnings per share- Basic | (0.77) | 1.03 | 4.40 | (1.10) | 2.07 | (1.09) | (0.14) | (0.01) | (0.37) | (0.59) |
| Loss from continuing operations | (0.18) | 0.97 | (0.83) | (1.10) | 0.10 | (1.12) | -- | -- | -- | -- |
| EPS (Diluted) : Discontinued operations | (0.59) | 0.00 | 5.23 | 0.00 | 1.94 | 0.03 | -- | -- | -- | -- |
| Earnings per share- Diluted | (0.77) | 0.97 | 4.40 | (1.10) | 2.04 | (1.09) | (0.14) | (0.01) | (0.37) | (0.59) |
| Weighted average common shares outstanding : Basic | 112.08 | 130.14 | 159.28 | 166.31 | 176.04 | 180.83 | 186.19 | 185.08 | 179.85 | 177.03 |
| Weighted average common shares outstanding : Diluted | 112.08 | 138.66 | 159.28 | 166.31 | 178.53 | 180.83 | 186.19 | 185.08 | 179.85 | 177.03 |